| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
EDTA iron sodium does not have a specific biological receptor target as it is a nutrient supplement rather than a pharmacologically active drug. The compound functions as an iron delivery system: the iron is released from the EDTA chelate in the gastrointestinal tract and absorbed via iron transport mechanisms, including DMT1 (divalent metal transporter 1) and ferroportin. The EDTA moiety may also have effects on metal ion bioavailability and enzyme inhibition. EDTA iron sodium is also a broad-spectrum molluscicide capable of killing snails and slugs. Its primary function is nutritional—providing bioavailable iron.
|
|---|---|
| ln Vitro |
In vitro, EDTA iron sodium exhibits no pharmacological activity as it is a nutrient supplement. Its utility is demonstrated in iron fortification studies, where it is evaluated for iron bioavailability, solubility, and stability. The compound has high solubility and minimal gastrointestinal irritation. In cell culture, iron uptake studies can be performed using intestinal cell lines (e.g., Caco-2) to assess iron absorption from NaFeEDTA compared to other iron sources. The compound is not tested for pharmacological activity in standard cell-based assays.
|
| ln Vivo |
In vivo, EDTA iron sodium is used as an iron fortifying agent to improve iron deficiency anemia. It has high bioavailability and is well-tolerated with minimal gastrointestinal side effects. The compound is absorbed in the gastrointestinal tract, and the iron is utilized for hemoglobin synthesis and other iron-dependent processes. EDTA iron sodium is used in flour, solid beverages, seasonings, biscuits, dairy products, and health foods. It is also used in children's nutrition as a source of iron. No therapeutic efficacy beyond iron supplementation is attributed to this compound.
|
| Enzyme Assay |
In vitro assays for EDTA iron sodium focus on iron bioavailability and stability rather than receptor binding. A standard protocol involves simulated gastrointestinal digestion followed by Caco-2 cell uptake studies. The compound is subjected to gastric and intestinal digestion conditions, and the soluble iron fraction is measured. Caco-2 cells are cultured in Transwell plates and treated with the digested samples. Iron uptake is measured by atomic absorption spectroscopy or using radioactive ⁵⁹Fe. For quality control, the compound is characterized by HPLC, titration, and elemental analysis. Purity is typically ≥99%.
|
| Cell Assay |
In vitro cell culture experiments with EDTA iron sodium typically involve intestinal epithelial cells (e.g., Caco-2) to study iron absorption. Cells are cultured in DMEM supplemented with 10% FBS and treated with EDTA iron sodium at concentrations ranging from 1-100 µM for 4-24 hours. Iron uptake is measured by atomic absorption spectroscopy or using radioactive isotopes. Cell viability is assessed using MTT assays. Ferritin expression is measured by ELISA or Western blotting as a marker of iron status. The compound is also used in studies of iron toxicity and oxidative stress.
|
| Animal Protocol |
In vivo animal studies with EDTA iron sodium typically involve iron deficiency models in rodents. A standard protocol involves feeding rats or mice an iron-deficient diet for 2-4 weeks to induce anemia, followed by oral administration of EDTA iron sodium at doses ranging from 1-10 mg Fe/kg daily for 2-4 weeks. Blood samples are collected for measurement of hemoglobin, hematocrit, serum iron, and ferritin. Iron absorption and tissue distribution are assessed by atomic absorption spectroscopy. The compound is also used in molluscicide studies for snail and slug control.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of EDTA iron sodium involve the absorption, distribution, metabolism, and excretion of iron. Following oral administration, iron is released from the EDTA chelate in the gastrointestinal tract and absorbed via DMT1. Absorbed iron is transported in the blood bound to transferrin and distributed to tissues, particularly bone marrow for erythropoiesis and the liver for storage. Iron is primarily excreted through the gastrointestinal tract via sloughed epithelial cells and in small amounts through urine and sweat. The EDTA moiety is excreted unchanged in urine.
|
| Toxicity/Toxicokinetics |
Toxicity Data
LC50 (Rat) > 2,050 mg/m³/4 hours Toxicological data for EDTA iron sodium indicate that it is safe for use as a food fortificant. It has minimal gastrointestinal irritation compared to other iron salts. The compound is not classified as a carcinogen, mutagen, or reproductive toxicant. At high doses, iron toxicity (hemochromatosis) may occur, but this is a risk with all iron supplements. The compound may cause mild gastrointestinal side effects at high doses. Standard laboratory precautions should be followed when handling the compound. It is approved for use in food products in many countries. |
| Additional Infomation |
See also: Ferrous Sulfate (related); Ferric cation (has active moiety) ... View More ...
EDTA iron sodium is a chelated iron compound widely used as an iron fortifying agent in food products. It is used in flour, solid beverages, seasonings, biscuits, dairy products, and health foods to improve iron deficiency anemia. The compound is also used in children's nutrition as a source of iron. It has high bioavailability, high solubility, and minimal gastrointestinal irritation. EDTA iron sodium is also a broad-spectrum molluscicide. It has not undergone clinical trials as a drug but is approved as a food additive. Its mechanism of action is nutritional—providing bioavailable iron. |
| Molecular Formula |
C10H12FEN2NAO8
|
|---|---|
| Molecular Weight |
367.05
|
| Exact Mass |
366.984
|
| CAS # |
15708-41-5
|
| PubChem CID |
27461
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.78 g/cm3 at 20 °C
|
| Boiling Point |
614.2ºC at 760mmHg
|
| Melting Point |
80 °C
|
| Flash Point |
325.2ºC
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
22
|
| Complexity |
293
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Fe+3].[Na+].[O-]C(C([H])([H])N(C([H])([H])C(=O)[O-])C([H])([H])C([H])([H])N(C([H])([H])C(=O)[O-])C([H])([H])C(=O)[O-])=O
|
| InChi Key |
MKWYFZFMAMBPQK-UHFFFAOYSA-J
|
| InChi Code |
InChI=1S/C10H16N2O8.Fe.Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;/q;+3;+1/p-4
|
| Chemical Name |
sodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;iron(3+)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 50 mg/mL (136.22 mM)
DMSO: 25 mg/mL (68.11 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7244 mL | 13.6221 mL | 27.2442 mL | |
| 5 mM | 0.5449 mL | 2.7244 mL | 5.4488 mL | |
| 10 mM | 0.2724 mL | 1.3622 mL | 2.7244 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
